<DOC>
	<DOCNO>NCT00568074</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare efficacy safety repaglinide Glurenorm速 Glucobay速 give mono-therapy Chinese subject treatment-naive type 2 diabetic .</brief_summary>
	<brief_title>Efficacy Safety Repaglinide , Glurenorm速 Glucobay速 Chinese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Gliquidone</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<criteria>Type 2 diabetes No previous treatment diabetes HbA1c : 7.012.0 % Type 1 diabetes Uncontrolled treated/untreated hypertension Any condition Investigator and/or Sponsor feel would interfere trial participation evaluation result Pregnancy , breastfeeding , intention become pregnant judge use inadequate contraceptive measure ( adequate contraceptive measure : sterilisation , intrauterine device ( IUD ) , oral contraceptive barrier method )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>